Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Ventyx Biosciences's VTX-2735?
VTX-2735 is a small molecule commercialized by Ventyx Biosciences, with a leading Phase II program in Familial Cold Autoinflammatory Syndrome...
VTX-2735 by Ventyx Biosciences for Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria): Likelihood of Approval
VTX-2735 is under clinical development by Ventyx Biosciences and currently in Phase II for Familial Cold Autoinflammatory Syndrome (Familial Cold...
Risk adjusted net present value: What is the current valuation of Ventyx Biosciences's VTX-2735?
VTX-2735 is a small molecule commercialized by Ventyx Biosciences, with a leading Phase II program in Familial Cold Autoinflammatory Syndrome...